Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 7/20 | 1.00 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8195740 | 1.00 | SLC6A9 (1.00) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL4430027 | 0.93 | SLC6A9 (0.88) | SLC6A9KCNH2SLC6A5 | |
| Bitopertin SCHEMBL29363611 | 0.91 | SLC6A9 (1.00) | SLC6A9KCNH2SLC6A5 | |
| Bitopertin SCHEMBL561853 | 0.91 | SLC6A9 (1.00) | SLC6A9KCNH2SLC6A5 | |
| Bitopertin SCHEMBL3772885 | 0.91 | SLC6A9 (1.00) | SLC6A9KCNH2SLC6A5 | |
| Bitopertin SCHEMBL29985866 | 0.91 | SLC6A9 (1.00) | SLC6A9KCNH2SLC6A5 | |
| Bitopertin SCHEMBL562490 | 0.91 | SLC6A9 (1.00) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL5043147 | 0.88 | SLC6A9 (0.79) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL5042089 | 0.87 | SLC6A9 (1.00) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL5037809 | 0.87 | SLC6A9 (1.00) | SLC6A9KCNH2SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2603219-B1 | COMBINATION OF GLYT1 COMPOUND WITH ANTIPSYCHOTICS | HOFFMANN LA ROCHE (CH) | 2014-09-17 | — | — | EP | claimed |
| EP-2603219-A1 | COMBINATION OF GLYT1 COMPOUND WITH ANTIPSYCHOTICS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-06-19 | — | — | EP | claimed |
| WO-2012019970-A1 | COMBINATION OF GLYT1 COMPOUND WITH ANTIPSYCHOTICS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | WO | claimed |
| US-20120035156-A1 | COMBINATION OF GLYT1 COMPOUND WITH ANTIPSYCHOTICS | HOFFMANN-LA ROCHE INC. | 2012-02-09 | — | — | US | claimed |
| US-7319099-B2 | Such as 1-{3-fluoro-4-[4-(2-isopropoxy-5-methanesulfonyl benzoyl)-piperazin-1-yl]-phenyl}-ethanone for treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia, attention deficit disorders, or Alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2008-01-15 | — | — | US | claimed |
| EP-1656361-B1 | PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-01-02 | — | — | EP | claimed |
| EP-1656361-A1 | PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | claimed |
| US-20050209241-A1 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. | 2005-09-22 | — | — | US | claimed |
| WO-2005014563-A1 | PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-17 | — | — | WO | claimed |
| EP-2603219-B1 | COMBINATION OF GLYT1 COMPOUND WITH ANTIPSYCHOTICS | HOFFMANN LA ROCHE (CH) | 2014-09-17 | — | — | EP | disclosed |
| EP-2603219-A1 | COMBINATION OF GLYT1 COMPOUND WITH ANTIPSYCHOTICS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-06-19 | — | — | EP | disclosed |
| WO-2012019970-A1 | COMBINATION OF GLYT1 COMPOUND WITH ANTIPSYCHOTICS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | WO | disclosed |
| US-20120035156-A1 | COMBINATION OF GLYT1 COMPOUND WITH ANTIPSYCHOTICS | HOFFMANN-LA ROCHE INC. | 2012-02-09 | — | — | US | disclosed |
| US-7605163-B2 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20080119486-A1 | BENZOYL-PIPERAZINE DERIVATIVES | JOLIDON SYNESE | 2008-05-22 | — | — | US | disclosed |
| US-7319099-B2 | Such as 1-{3-fluoro-4-[4-(2-isopropoxy-5-methanesulfonyl benzoyl)-piperazin-1-yl]-phenyl}-ethanone for treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia, attention deficit disorders, or Alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2008-01-15 | — | — | US | disclosed |
| EP-1656361-B1 | PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-01-02 | — | — | EP | disclosed |
| EP-1656361-A1 | PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-20050209241-A1 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. | 2005-09-22 | — | — | US | disclosed |
| WO-2005014563-A1 | PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209241-A1 | Benzoyl-piperazine derivatives | SLC1A2, SLC18A2, SLC6A7 | SLC6A9 82/4885KCNH2 719/4885SLC6A5 9/4885 |
| US-20120035156-A1 | COMBINATION OF GLYT1 COMPOUND WITH ANTIPSYCHOTICS | SLC6A4, SLC1A2, SLC1A1 | SLC6A9 13/4885KCNH2 742/4885SLC6A5 5/4885 |
| US-20080119486-A1 | BENZOYL-PIPERAZINE DERIVATIVES | SLC1A2, SLC18A2, SLC6A7 | SLC6A9 82/4885KCNH2 719/4885SLC6A5 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.